Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels
Our findings demonstrate that aducanumab specifically targets HMW AβOs, mitigating their neurotoxic effects by restoring intracellular calcium homeostasis. These results provide mechanistic insight into aducanumab's therapeutic action and support its potential role in modifying AD pathology by selectively neutralizing Aβ species.
Authors
- Tri Huu Doan (ORCID: https://orcid.org/0000-0002-1365-2708)
- Thierry Bussière (ORCID: https://orcid.org/0000-0002-6818-4876)
- Brian J. Bacskai (ORCID: https://orcid.org/0000-0002-2584-6702)
- Ksenia V. Kastanenka (ORCID: https://orcid.org/0000-0002-3727-0317)
- Yutian Fan
- Xueying Wang (ORCID: https://orcid.org/0000-0002-2399-8083)
- Lu Yu (ORCID: https://orcid.org/0000-0003-4852-0008)
Institutions
- Biogen (United States) (US)
- Xuzhou Medical College (CN)
- Norwood Hospital (US)
- Massachusetts General Hospital (US)
- Moderna Therapeutics (United States) (US)
- MaineGeneral Medical Center (US)
- Brandeis University (US)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1186/s13195-025-01812-9
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen
- Xuzhou Medical University